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Abstract
Introduction: In clinical trials, ordinal outcome measures are often dichotomized into two categories. In traumatic
brain injury (TBI) the 5-point Glasgow outcome scale (GOS) is collapsed into unfavourable versus favourable
outcome. Simulation studies have shown that exploiting the ordinal nature of the GOS increases chances of
detecting treatment effects. The objective of this study is to quantify the benefits of ordinal analysis in the real-life
situation of a large TBI trial.
Methods: We used data from the CRASH trial that investigated the efficacy of corticosteroids in TBI patients (n =
9,554). We applied two techniques for ordinal analysis: proportional odds analysis and the sliding dichotomy
approach, where the GOS is dichotomized at different cut-offs according to baseline prognostic risk. These
approaches were compared to dichotomous analysis. The information density in each analysis was indicated by a
Wald statistic. All analyses were adjusted for baseline characteristics.
Results: Dichotomous analysis of the six-month GOS showed a non-significant treatment effect (OR = 1.09, 95% CI
0.98 to 1.21, P = 0.096). Ordinal analysis with proportional odds regression or sliding dichotomy showed highly
statistically significant treatment effects (OR 1.15, 95% CI 1.06 to 1.25, P = 0.0007 and 1.19, 95% CI 1.08 to 1.30, P =
0.0002), with 2.05-fold and 2.56-fold higher information density compared to the dichotomous approach
respectively.
Conclusions: Analysis of the CRASH trial data confirmed that ordinal analysis of outcome substantially increases
statistical power. We expect these results to hold for other fields of critical care medicine that use ordinal outcome
measures and recommend that future trials adopt ordinal analyses. This will permit detection of smaller treatment
effects.
Introduction
Traumatic brain injury (TBI) is a major health and
socio-economic problem throughout the world. Basic
research has elucidated many of the pathophysiological
mechanisms underpinning secondary damage and many
neuroprotective agents have been developed to counter-
act these mechanisms. Since the 1980s, at least 33 ran-
domized controlled phase III trials have been performed
to investigate the effectiveness of new therapeutic
interventions in TBI, but none has convincingly demon-
strated benefit in the overall population [1]. Heterogene-
ity of the population and limitations of the conventional
statistical analysis of TBI trials contribute to this lack of
success [2,3]. We recently published a set of recommen-
dations for improving the design and analysis of future
TBI trials [4]. These recommendations were mainly
d e r i v e df r o ms i m u l a t i o ns t u d i e sa n di n c l u d et h eu s eo f
relatively broad enrolment criteria, covariate adjustment
and ordinal rather than dichotomous outcome analysis.
In most phase III TBI trials, the 5-point Glasgow Out-
come Scale is used as the primary outcome measure,
usually measured at six months after injury, and
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Severe Disability) versus favourable outcome (Moderate
Disability or Good Recovery) (Table 1). Similar
approaches are often used in the analysis of trials con-
ducted for other indications. For example, in stroke the
modified Rankin scale, which is also an ordinal scale,
consisting of six categories, is commonly collapsed into
a binary scale. This dichotomous outcome is then ana-
lysed with a chi-squared test or with binary logistic
regression. Simulation studies have demonstrated that
ordinal outcome analysis in TBI trials can increase sta-
tistical power [5]. These results have not yet been vali-
dated in empirical data. The aim of this study is to
investigate whether the benefits of an ordinal analysis
w o u l db eu p h e l do na n a l y s i so ft h el a r g e s tt r i a li nT B I
ever, which did demonstrate a true (but negative) treat-
ment effect.
Materials and methods
Data
We used the individual patient data of the MRC CRASH
trial into which 10,008 patients were enrolled.
The CRASH trial (Corticosteroid Randomisation After
Significant Head Injury) was an international, rando-
mised, placebo-controlled trial designed to investigate
the effect of early administration of methylprednisolone
on the risk of death and disability after head injury. Full
results have been reported [6,7]. Enrolment was stopped
in May 2004, following demonstration of a higher 14-day
mortality rate in the active treatment arm (21.1% versus
17.9% deaths; P = 0.0001). Outcome at six months was
available for 9,554 patients. The current study was
exempt from institutional review board approval.
Conventional dichotomous outcome analysis
We first estimated the effect of the treatment on the
six-month GOS, dichotomized as unfavourable versus
favourable, with binary logistic regression. The treat-
ment effect was adjusted for four baseline covariates:
age, Glasgow Coma Scale (GCS), pupillary reactivity and
presence of major extracranial injury. Age was handled
as a continuous variable and GCS as a categorical vari-
able (range 3 to 15). Pupillary reactivity was grouped
into three categories: both pupils reactive, one reactive
and none reactive to light. The presence of major
extracranial injury was included as a binary variable,
having a positive value when patients had an extracra-
nial injury that required hospital admission on its own.
Subsequently, we used two approaches exploiting the
ordinal nature of the GOS: a proportional odds logistic
regression model and the sliding dichotomy approach.
Proportional odds logistic regression
A proportional odds logistic regression model was fitted
with the GOS collapsed to a 4-point ordinal scale
(Severe Disability and Vegetative State were taken
together) as the outcome variable. The proportional
odds model has the same structure as the binary logistic
regression model, but uses an ordinal outcome variable
with more than two possible categories. It estimates a
common odds ratio over all possible cut-offs of the out-
come scale. The common odds ratio is formally valid if
the odds ratios for each cut-off are the same (the pro-
portional odds assumption). We can, however, interpret
the common odds ratio as a summary measure of treat-
ment effect, even if the odds ratios differ by cut-off [8].
The common odds ratio can also be interpreted as the
average shift over the total ordinal outcome scale caused
by the treatment under study [5,9,10].
Sliding dichotomy
The sliding dichotomy approach dichotomizes the GOS
into a binary measure, but the point of dichotomy is tai-
lored to each individual patient’s baseline prognosis [11].
For example, for a patient with an excellent prognosis
only good recovery may be considered as a favourable
outcome, whereas for a patient with a very poor prog-
nosis, survival may be regarded as a favourable outcome.
First, the baseline prognostic risk of each patient was
estimated by calculating the probability of unfavourable
outcome with a prediction model including the following
variables: age, GCS, pupillary reactivity, and presence of
major extracranial injury [12]. Subsequently, patients
were divided into three prognostic bands of equal size,
that is, for the best, intermediate and worst prognosis.
For each band a separate cut-off on the GOS was defined
and a new outcome variable was generated. For example,
in the best prognosis band we only considered Good
Recovery as a favourable outcome. The effect of treat-
ment on this newly constructed dichotomous outcome
was then estimated with binary logistic regression, with
stratification by prognostic band and adjustment for the
four covariates mentioned above. The pooled sliding
dichotomy odds ratio can be interpreted as the effect of
treatment on outcomes being worse than expected [11].
Comparison of the different approaches
We calculated Wald statistics, based on the coefficients
of the treatment effect and the corresponding standard
Table 1 The Glasgow Outcome Scale and its traditional
dichotomy in favourable versus unfavourable outcome
Dead
Vegetative State Unfavourable
Severe Disability
Moderate Disability Favourable
Good Recovery
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can be interpreted as the gain in information density
and is, therefore, a suitable measure for the efficiency of
the different approaches.
We adjusted the treatment effect for four baseline
covariates in all analyses (age, GCS, pupillary reactivity,
major extracranial injury) [12,13]. Missing data occurred
for 509 patients on pupillary reactivity and 196 on the
presence of extracranial injury. These missing covariates
were imputed with a multiple imputation model. Statis-
tical analyses were performed in R Statistical Software
version 2.7.2 using the Design library (R Foundation for
Statistical Computation, Vienna, Austria).
Results
The CRASH trial included 10,008 patients. We excluded
454 patients with missing six-month GOS score, leaving
9,554 for the analyses. Median age was 33 years, and
8 1 %o ft h ep a t i e n t sw e r em a l e( T a b l e2 ) .A ts i xm o n t h s
after injury, 2,323 (24%) patients had died and 3,557
(37%) had an unfavourable outcome (Figure 1). Dichoto-
mous analysis of the six-month GOS showed a non-sig-
nificant adjusted odds ratio (OR) of 1.09 (95% CI 0.98
to 1.21, P = 0.096).
The use of different splits than the conventional
favourable vs. unfavourable outcome resulted in rather
different estimates of the treatment effect (Table 3).
Further, the estimated treatment effect was non-signifi-
cant when the conventional dichotomy was used, while
it was significant when the split was taken at less than
Good Recovery vs. Good Recovery (OR 1.12, 95% CI
1.01 to 1.23, P = 0.024) and death vs. survival (OR 1.27,
95% CI 1.13 to 1.43, P < 0.0001). Application of the pro-
portional odds logistic regression model gave an esti-
mated common odds ratio of 1.15 (95% CI 1.06 to 1.25)
with a P-value of 0.0007.
With the sliding dichotomy approach we divided the
study population into three bands of equal numbers,
based on the individual prognostic risk for unfavourable
outcome of each patient (Table 4). For each prognostic
band a different split for the dichotomization was used
(better versus worse than expected). In the ‘best prog-
nosis’ band the split was taken at Good Recovery versus
worse than Good Recovery, in the ‘intermediate prog-
nosis’ band at Moderate Disability or better versus
Severe Disability or worse, and in the ‘worst prognosis’
band between death and survival. An unadjusted odds
ratio was calculated for each prognostic band. These
odds ratios varied between 1.06 (95% CI 0.91 to 1.23, P
= 0.45) for the ‘intermediate prognosis’ band and 1.28
(95% CI 1.11 to 1.47, P = 0.0006) for the ‘worst prog-
nosis’ band. Unadjusted and adjusted pooled odds ratios
were similar (1.17, 95% CI 1.07 to 1.27, P = 0.0003 and
1.19, 95% CI 1.08 to 1.30, P = 0.0002).
T h el o g i s t i cr e g r e s s i o na n alysis with dichotomized
GOS resulted in a Wald statistic for the treatment effect
of 1.66 (P = 0.096). Ordinal analysis with a proportional
odds model gave a 2.05-fold higher Wald statistic (3.41,
P = 0.0007). The sliding dichotomy approach resulted in
an even larger Wald statistic of 3.69 (P = 0.0002), indi-
cating a 2.56-fold increase in information density.
Discussion
Analysis of the MRC CRASH trial data showed that
ordinal analysis of the GOS resulted in substantially
greater statistical power to detect a treatment effect
with equal sample size. Whilst results obtained with the
conventional analysis of the dichotomized GOS were
non-significant, those obtained with ordinal analysis
were highly significant. With ordinal analysis, a 2- to
2.5-fold gain in information density was demonstrated,
compared to the dichotomized analysis. Simulation stu-
dies had already suggested the potential for ordinal ana-
lysis to increase statistical power in TBI trials, but our
current study has proven the value of this approach in
the empirical data of a large trial with a true treatment
effect.
Earlier research has demonstrated that adjustment for
strong predictors of outcome (covariate adjustment)
may result in a substantial increase in statistical power
and trial efficiency [13-15]. In the IMPACT database,
we found that the required sample size for a RCT could
potentially be reduced by around 25% when covariate
adjustment would be applied with seven strong
Table 2 Baseline characteristics of patients enrolled in
the CRASH trial with Glasgow Outcome Scale score
available
Corticosteroid
(n = 4,800)
Placebo
(n = 4,754)
Age (median, IQR) 33, 23 to 47 32, 23 to 48
Gender
Male 3,892 (81.1%) 3,824 (80.4%)
Glasgow Coma Scale
Severe (3 to 8) 1,925 (40.1%) 1,890 (39.8%)
Moderate (9 to 12) 1,477 (30.8%) 1,405 (29.6%)
Mild (13 to 14) 1,398 (29.1%) 1,459 (30.7%)
Pupillary reactivity
Both reactive to light 3,860 (80.4%) 3,822 (80.4%)
One reactive to light 270 (5.6%) 294 (6.2%)
Both not reactive to
light
412 (8.6%) 387 (8.1%)
Missing 258 (5.4%) 251 (5.3%)
Major extracranial injury
Yes 1,106 (23.0%) 1,039 (21.9%)
No 3,600 (75.0%) 3,613 (76.0%)
Missing 94 (2.0%) 102 (2.1%)
IQR: interquartile range.
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adjustment in all analyses in the present study.
Why is the use of ordinal outcome analysis beneficial?
The common practice of collapsing an ordinal outcome
measure to a binary scale results in a loss of information
[16]. Moreover, dichotomization gives priority to one
particular transition in the outcome scale: in the case of
t h eG O St h i si st h ec h a n g ef r o ms e v e r ed i s a b i l i t yt o
moderate disability. Patients with a relatively extreme
prognosis have little potential to contribute to the detec-
tion of a treatment effect on an ordinal functional out-
come scale, when this scale is dichotomized for the
analysis [17]. A patient with a very good prognosis will
almost inevitably have a favourable outcome, even with-
out the benefits of a new effective therapy. In contrast,
f o rp a t i e n t sw i t hav e r yp o o rp r o g n o s i si ti se x t r e m e l y
u n l i k e l yt oh a v eaf a v o u r a b l eo u t c o m ea ts i xm o n t h s ,
even with a very beneficial new treatment. This does
not mean that these patients may not benefit from the
treatment, but simply that the fixed split for dichotomis-
ing the outcome measure is not appropriate for these
s i t u a t i o n s .W h e nt h eo u t c o m ei sa n a l y s e di na no r d i n a l
way, all patients can contribute to the detection of a
treatment effect.
The idea of exploiting the ordinal nature of ordered
outcome scales is far from a new concept in the statisti-
cal community [18]. Nevertheless, this approach has not
been applied to the analysis of clinical trials on a regular
basis. The sliding dichotomy approach was recently
applied for the primary efficacy in a number of trials:
the PAIS trial in stroke [19], the STICH trial in sponta-
neous intracerebral hemorrhage [20], and the Pharmos
trial in TBI [21]. The proportional odds model was used
in several neurological trials, for example, in the GAIN
International trial [22] and the SAINT I trial [23].
Inherent to the proportional odds model is the pro-
portional odds assumption, that is, that the treatment
effect is constant across all cut-offs of the outcome
scale. This assumption may partly be violated in empiri-
cal data. We, therefore, recommend reporting the odds
ratios per cut-off if a common odds ratio is reported as
the summary measure of the treatment effect. Indeed,
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Figure 1 Distribution of the Glasgow Outcome Score at six months after injury. Data from the CRASH trial (n = 9,554). SD, severe disability
(including vegetative state); MD, moderate disability; GR, good recovery
Table 3 Analysis of the treatment effect according to different dichotomizations and proportional odds logistic
regression
Adjusted odds ratio^ (95% CI) Wald statistic P-value
Dichotomous odds ratios
Less than good vs. good recovery 1.12 (1.01 to 1.23) 2.26 0.024
Unfavourable vs. favourable outcome 1.09 (0.98 to 1.21) 1.66 0.096
Death vs. survival 1.27 (1.13 to 1.43) 4.16 < 0.0001
Common odds ratio (proportional odds model) 1.15 (1.06 to 1.25) 3.41 0.0007
Analyses are based on the six-month Glasgow Outcome Scale. Data from the CRASH trial (n = 9,554).
An odds ratio > 1 indicates an adverse effect of corticosteroids.
^ Adjustment for age, GCS, pupillary reactivity and major extracranial injury
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all cut-offs for the GOS (Table 2). Also, some variation
was seen in the odds ratios across prognostic bands for
the sliding dichotomy (Table 3). The proportional odds
assumption was formally tested with the ‘PROC LOGIS-
TIC’ test from the SAS software package (SAS Institute
Inc., Cary, NC, USA) and was found to be violated. This
was confirmed by a graphical test in R software (the
‘residuals’ function from the Design library) to test for
parallelism. In a previous study we simulated a non-pro-
portional treatment effect, that is, a treatment that only
affected mortality and did not cause a shift for the other
categories of the GOS. We found to our surprise that
the statistical power of ordinal analyses (proportional
odds or sliding dichotomy) remained higher than a
dichotomous analysis at the ‘correct’ cut-off (mortality
vs. survival) [11]. This robust gain in statistical power is
a clear advantage of ordinal analysis, even if one were to
object to interpretation of a summary odds ratio when
underlying assumptions are violated [8].
The choice between the two ordinal approaches
involves primarily a value judgement. The sliding
dichotomy approach and its explanation (the effect of
treatment on outcomes being worse than expected) may
be particularly appealing for clinicians, but it requires a
(validated) prognostic model to identify each patient’s
baseline prognostic risk. The proportional odds method
does not necessarily require such a model, but may not
have a proper interpretation if effect estimates vary sub-
stantially by cut-off (a violation of the proportional odds
assumption). A pragmatic approach is to focus more on
the underlying concept of ‘shift analysis’, instead of
emphasizing the formal assumptions of this model.
Both approaches to ordinal outcome analysis that were
investigated in the present study resulted in substantial
power increase. Therefore, we strongly recommend
incorporating ordinal methods in the analysis of future
trials when an ordered outcome measure is considered.
We do not advocate that this power increase should
motivate reduced sample sizes for future trials. Since
most TBI trials that were published in the past decades
have been underpowered [24], the power increase that
results from ordinal analysis can thus be used to
increase the chance of detecting smaller, but clinically
relevant, treatment effects with the same sample size.
The use of ordinal outcome scales is not unique to
TBI, but is common to many fields of clinical research.
Equally common is the practice of dichotomising ordinal
outcome measures. In the field of stroke research, the
modified Rankin Scale and the Barthel Index are often
used as primary efficacy endpoints - and are also dichot-
omized [25,26]. The Optimising Analysis of Stroke
Trials (OAST) Collaboration has shown the benefit of
ordinal analysis in the field of stroke [27]. Other exam-
ples of ordinal outcome scales can be found in cardiol-
ogy (for example, NYHA Functional Classification for
heart failure), vascular surgery (for example, Rutherford
Classification for peripheral artery disease) and pain
management (for example, Visual Analogue Scale). The
widespread use of ordinal outcome measures and the
persisting practice of collapsing these measures into a
binary outcome indicate that our findings in this case
Table 4 Analysis of the Glasgow Outcome Scale with the sliding dichotomy approach
Dead SD MD GR Worse than
expected
Better than
expected
Odds ratio
(95% CI)
Wald
statistic
P-
value
Best prognosis Corticosteroid 67 86 274 1,162 427 1,162 1.22 (1.03 to
1.43)
0.017
Placebo 59 84 228 1,227 371 1,227
Intermediate prognosis Corticosteroid 282 215 365 748 497 1,113 1.06 (0.91 to
1.23)
0.45
Placebo 225 241 357 749 466 1106
Worst prognosis Corticosteroid 899 280 212 210 899 702 1.28 (1.11 to
1.47)
0.0006
Placebo 791 328 228 237 791 793
Pooled odds ratio,
unadjusted
1.17 (1.07 to 1.27) 3.67 0.0003
Pooled odds ratio,
adjusted^
1.19 (1.08 to 1.30) 3.69 0.0002
The prognosis bands were created with model containing the variables age, GCS, pupillary reactivity and major extracranial injury. Odds ratios were given by
prognosis band, for the unadjusted treatment effect. Pooled odds ratios were given for the unadjusted and adjusted treatment effect. An odds ratio > 1 indicates
an adverse effect of corticosteroids. Patients with better outcome than expected are underlined. Data from the CRASH trial (n = 9,554).
^ Adjustment for age; GCS, pupillary reactivity and major extracranial injury.
GCS, Glasgow Coma Scale; SD, Severe Disability (including Vegetative State); MD, Moderate Disability; GR, Good Recovery; OR, odds ratio.
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TBI alone. We consider our results directly relevant to
clinical trials in other fields of medicine that use ordinal
outcome measures, especially if outcomes occur over
the full range of the scale.
Conclusions
We conclude that the application of ordinal outcome
analysis substantially increases the power of a clinical
trial. We recommend that future randomized trials,
which use an ordinal outcome measure as efficacy para-
meter, adopt ordinal outcome analysis in order to facili-
tate detection of smaller treatment effects.
Key messages
￿ None of the phase III clinical trials for Traumatic
Brain Injury (TBI) has shown an overall significant
treatment effect. Inefficient analysis of trials may
contribute this the failure.
￿ Dichotomous analysis of an ordinal outcome scale
in clinical trials results in loss of information. Pre-
vious simulation studies suggested that ordinal out-
come analysis could substantially improve statistical
power of a clinical TBI trial.
￿ T h ep r e s e n ts t u d yg i v e sar e a l - l i f ee x a m p l eo ft h e
benefit two approaches to ordinal outcome analysis
in a large TBI trial (the CRASH trial).
￿ Both approaches to ordinal analysis showed highly
significant treatment effects, increased statistical
power and a 2.1- to 2.6-fold increase in information
density.
￿ We recommend that future trials adopt ordinal
outcome analysis, in order to facilitate detection of
smaller treatment effects.
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